TSHA
Taysha Gene Therapies, Inc.
Next earnings Aug 10, 2026 · consensus $-0.12 EPS, $694K rev
Last earnings +0.6% on 2026-05-06
$6.86
▲ +5.05%$6.86▲ +169.02%
over 1Y
L $2.31EODHDH $6.98
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+5.1%
1W+17.3%
1M+22.7%
3M+66.1%
YTD+30.7%
1Y+169.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 19 analysts
Buy
Revenue grew 17.3% YoY; but unprofitable (net margin -1115.3%).
Taysha Gene Therapies, Inc. shows $9.77M in FY2025 revenue (+17.3% YoY), a -1115.3% net margin, and -44.1% ROE.
Sources: SEC EDGAR (CIK 0001806310, latest 10-Q filed 2026-05-06) · EODHD · as of 6/24/2026, 9:46:07 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.